Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Net Cash Flow (2016 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Net Cash Flow for 16 consecutive years, with $19.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow fell 74.37% year-over-year to $19.3 million, compared with a TTM value of $191.6 million through Dec 2025, down 49.56%, and an annual FY2025 reading of $191.6 million, down 49.56% over the prior year.
  • Net Cash Flow was $19.3 million for Q4 2025 at Catalyst Pharmaceuticals, down from $37.1 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $172.8 million in Q1 2024 and bottomed at -$150.1 million in Q1 2023.
  • Average Net Cash Flow over 5 years is $28.5 million, with a median of $26.9 million recorded in 2022.
  • The sharpest move saw Net Cash Flow soared 851.36% in 2021, then plummeted 2267.58% in 2023.
  • Year by year, Net Cash Flow stood at $16.6 million in 2021, then soared by 154.86% to $42.3 million in 2022, then tumbled by 60.63% to $16.7 million in 2023, then skyrocketed by 351.38% to $75.2 million in 2024, then tumbled by 74.37% to $19.3 million in 2025.
  • Business Quant data shows Net Cash Flow for CPRX at $19.3 million in Q4 2025, $37.1 million in Q3 2025, and $72.1 million in Q2 2025.